May 17, 2019 — InvestorsHub NewsWire — Microcap Speculators — Growth based biotech stocks are one of the few sectors that aren’t negatively affected by Trump’s trade war. Below are a few to start your research on.
One company getting closer to a human trial, Propanc Biopharma, Inc. (USOTC: PPCB), initiated development of a bio-analytical assay intended to quantify the active ingredients of the company’s lead product candidate, PRP, in preparation for human trials in March ‘19. This is just one step closer for a company that has been making steady progress over the past year or so.
The companies we’re highlighting today include: Propanc Biopharma, Inc. (USOTC: PPCB), Aurora Cannabis, Inc. (NYSE: ACB), ImmunoGen, Inc. (NASDAQ: IMGN), PDS Biotechnology Corporation (NASDAQ: PDSB), and Advaxis, Inc. (ADXS).
Propanc Biopharma, Inc. (USOTC: PPCB) (Market Cap: $3.155M; Share Price: $0.0078), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, was granted FDA Orphan Drug Designation status for its PRP treatment of pancreatic cancer almost a year back. This qualifies the company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S. The company is also close to first-in-human studies.
PPCB announced that the company has appointed Dr. Ralf Brandt to its Scientific Advisory Board (SAB). He will provide significant translational research expertise and clinical support advisory support services to the company’s drug development pipeline.
PPCB is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.
PPCB has a growing patent portfolio that larger healthcare companies could be very interested in. It is among many biotech’s that could be considered a bit oversold due to current market conditions.
Aurora Cannabis, Inc. (NYSE: ACB) (Market Cap: $9.134B; Share Price: $8.89) reported a 20% jump in quarterly net revenue on Tuesday, as Canada’s legalization of recreational cannabis late last year boosted demand.
The Edmonton, Alberta-based company’s net revenue rose to C$65.2 million ($48.44 million) from C$54.2 million ($40.27 million) in the second quarter. ($1 = 1.3459 Canadian dollars).
ImmunoGen, Inc. (NASDAQ: IMGN) (Market Cap: $294.576M; Share Price: $1.97) plunged more than 30% on Wednesday after the company revealed that the U.S. Food and Drug Administration has recommended further trials to “evaluate the safety and efficacy” of one of its cancer-fighting treatments. ImmunoGen said in statement that it had requested a meeting with FDA officials to discuss the results of its Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy – a treatment it has been developing for patients with certain forms of ovarian cancer.
PDS Biotechnology Corporation (NASDAQ: PDSB) (Market Cap: $41.288M; Share Price: $7.72) announced a peer-reviewed publication supporting the novel mechanisms of action of its proprietary Versamune® platform in cancer immunotherapy. The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response” was published online on May 3, 2019 in the Journal of Immunology, and describes the way PDS’ Versamune® platform recruits and activates killer T-cells to recognize and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack. The article will appear in print in the June 2019 issue of the Journal.
Advaxis, Inc. (ADXS) (Market Cap: $24.178M; Share Price: $3.02), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting expects to be paid $3,000 for the article directly from PPCB. All payments were made directly by Propanc Biopharma, Inc. (USOTC: PPCB) to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. PPCB was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: [email protected]
Country: United States
SOURCE: Microcap Speculators